Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Date
2023-12Author
Metadata
Show full item recordAbstract
In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morning…’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139, 25/125 and 56/125’ were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by…’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’ The original article has been corrected.
Collections
Publisher
Place of Publication
Journal
Volume
Issue
Pagination
Author URL
Recommended, similar items
The following license files are associated with this item: